Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester image

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Posted on: Jun 29, 2022
Play Episode
Also available on
Overview

Dr. Jane Liesveld
University of Rochester
Interview Date: June 29, 2022

 

The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients, occuring in up to 37% of adult cases. FLT3 mutations have historically been harder to treat with poorer outcomes, however, with combination therapies using targeted drugs such as FLT3 inhibitors, outcomes have improved. In this show, Dr. Jane Liesveld, an AML expert from the University of Rochester, shared with us the FLT3 inhibitor options currently available and in development, as well as research from several recent clinical trials exploring new FLT3 inhibitor drugs.

Thanks to Our Episode Sponsor

User uploaded media

On this episode
Healthtree contact Kerith Amen

Kerith Amen

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Healthtree contact Jane Liesveld, MD

Jane Liesveld, MD

Professor of Medicine in the Division of Hematology and Oncology and Clinical Director of the Blood and Marrow Transplantation Program at the University of Rochester School of Medicine and Dentistry

Transcript

Related Content